Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) plans several July 2026 scientific and investor appearances. The company will present at the OIS Retina Innovation Summit on July 14 in Montréal and at the ASRS 44th Annual Meeting July 15–18, highlighting OTX-TKI Phase 3 SOL-1 results and nAMD data.

Ocular will also join the HC Wainwright 6th Annual Ophthalmology Virtual Conference on July 22 with a webcast fireside chat for investors.

News Market Reaction – OCUL

-3.56%

2 alerts

-3.56% Session close to close

-16.7% Trough Tracked

$2.15B Market Cap

5.15K Volume

In the Jul 1 session, OCUL declined 3.56%, reflecting a moderate negative market reaction. Argus tracked a trough of -16.7% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights multiple July retina and investor events, including Phase 3 SOL-1 data ...

Analysis

This announcement highlights multiple July retina and investor events, including Phase 3 SOL-1 data and a fireside chat, extending visibility for AXPAXLI and OTX-TKI. With an active shelf and Net Selling insiders, investors may watch forthcoming data quality closely.

Key Figures

OIS Retina meeting: 9th Annual ASRS meeting: 44th Annual HC Wainwright event: 6th Annual +5 more

8 metrics

OIS Retina meeting 9th Annual OIS Retina Innovation Summit in Montréal on July 14, 2026

ASRS meeting 44th Annual American Society of Retina Specialists meeting July 15–18, 2026

HC Wainwright event 6th Annual HC Wainwright Ophthalmology Virtual Conference on July 22, 2026

Phase 3 SOL-1 window 8:15 – 8:45 AM EDT ASRS presentation slot for Phase 3 SOL-1 OTX-TKI results

Real-world data talk 8:50 – 8:53 AM EDT ASRS presentation on Vestrum database real-world nAMD utilization

Satellite symposium 6:00 – 7:30 PM EDT ASRS symposium on durability and sustained disease control in nAMD

Fireside chat 4:30 – 5:00 PM EDT HC Wainwright virtual ophthalmology conference investor session

Webcast replay period at least 30 days Investor fireside chat replay availability on company website

Historical Context

5 past events · Latest: Jun 22 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 22	Inducement equity grants	Neutral	+1.4%	Inducement stock option and RSU grants for a new senior executive hire.
Jun 17	FDA NDA alignment	Positive	+7.8%	Company highlighted FDA alignment and planned 4Q 2026 NDA for AXPAXLI.
Jun 05	Inducement equity grants	Neutral	-6.3%	Inducement plan grants of options and RSUs to several new employees.
Jun 04	Conference participation	Positive	+5.4%	Clinical Trials at the Summit participation focused on OTX-TKI and retina programs.
Jun 02	Investor Day announcement	Positive	-6.9%	Announcement of a June 17 Investor Day covering AXPAXLI and retinal pipeline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent conference and event-related headlines have produced sharp but mixed stock reactions, with some catalysts aligning positively and others seeing notable downside moves.

Key Terms

intravitreal, neovascular age-related macular degeneration, anti-vegf, phase 3

4 terms

intravitreal medical

"Presentation: Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration"

An intravitreal treatment is one given by injecting medicine directly into the gel-like center of the eye, delivering drugs straight to the site of retinal disease rather than through pills or eye drops. Investors care because this delivery method affects development costs, regulatory review, clinical risk, manufacturing and distribution complexity, and reimbursement — all factors that influence a therapy’s commercial potential.

neovascular age-related macular degeneration medical

"in Neovascular Age-Related Macular Degeneration: Efficacy and Safety Results from the Phase 3 SOL-1 Trial"

A progressive eye disease in older adults where abnormal blood vessels grow beneath the central retina and leak fluid or blood, quickly damaging sharp central vision used for reading and recognizing faces. For investors, it matters because it creates ongoing demand for medical treatments, diagnostics and follow-up care, and outcomes hinge on clinical trial results, regulatory approvals and reimbursement decisions that can sharply affect the value of companies developing therapies — like a chronic market need driven by a high-impact illness.

anti-vegf medical

"Session: Beyond Anti-VEGF: Emerging Durable Therapies in Neovascular AMD"

Anti-VEGF describes medicines or treatments that block a protein called vascular endothelial growth factor (VEGF), which tells the body to grow new blood vessels. By shutting off that signal, these therapies can slow or stop unwanted vessel growth and leaking in diseases such as certain eye disorders and cancers. Investors watch anti-VEGF programs because they can command large markets, affect patient outcomes, and drive drug sales, royalties, and valuation like controlling a major pipeline.

phase 3 medical

"Efficacy and Safety Results from the Phase 3 SOL-1 Trial Results"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026.

Upcoming Scientific Conferences:

9^th Annual OIS Retina Innovation Summit (OIS Retina 2026): July 14, 2026
Montréal, Quebec

• Presentation: Ocular Therapeutix: Retina Experience Redefined
  Presentation Date/Time: Tuesday, July 14, 2026, 11:37 – 11:44 AM EDT
  Presenter: Peter K. Kaiser, MD, Chief Development Officer

• Panel Title: The Impact of Recent FDA Guidance on Drug Development
  Panel Date/Time: Tuesday, July 14, 2026, 4:40 – 5:20 PM ET
  Panel Moderator: Pravin U. Dugel, MD, Executive Chairman, President and CEO

The American Society of Retina Specialists (ASRS) 44^th Annual Meeting: July 15 - 18, 2026
Montréal, Quebec

• Presentation: Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration: Efficacy and Safety Results from the Phase 3
  SOL-1 Trial Results
  Session: Beyond Anti-VEGF: Emerging Durable Therapies in Neovascular AMD
  Presentation Date/Time: Thursday, July 16, 2026, 8:15 – 8:45 AM EDT
  Presenter: Dilsher S. Dhoot, MD

• Presentation: Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum Database
  Session: Real-world nAMD: Utilization, Outcomes, and Long-Term Anti-VEGF Data
  Presentation Date/Time: Thursday, July 16, 2026, 8:50 – 8:53 AM EDT
  Presenter: Andrew A. Moshfeghi, MD, MBA, FASRS

• On-Demand Paper Title: Anti-VEGF Treatment Patterns and Long-Term Vision Outcomes in Patients with nAMD in the IRIS Registry
  Session Date/Time: On-demand papers will be continually available for viewing throughout the meeting
  Presenter: Priya Vakharia, MD

• Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
  Session: Satellite Symposia
  Symposium Date/Time: Thursday, July 16, 2026, 6:00 – 7:30 PM EDT
  Faculty: Arshad M. Khanani, MD; Dilsher S. Dhoot, MD; Mark R. Barakat, MD; Peter K. Kaiser, MD, Chief Development Officer; and Jeffrey S. Heier, MD, Chief Scientific Officer

Exact medical conference presentation times may be subject to change.

Upcoming Investor Conference:

HC Wainwright 6^th Annual Ophthalmology Virtual Conference:
Date: Wednesday, July 22, 2026
Fireside Chat: 4:30 – 5:00 PM EDT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Virtual

A live webcast of the fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days following the presentation.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

What conferences will Ocular Therapeutix (NASDAQ: OCUL) attend in July 2026?

Ocular Therapeutix will attend multiple retina-focused scientific meetings in Montréal and an ophthalmology investor event in July 2026. According to Ocular Therapeutix, these include OIS Retina 2026, the ASRS 44th Annual Meeting, and the HC Wainwright 6th Annual Ophthalmology Virtual Conference.

When is Ocular Therapeutix presenting OTX-TKI Phase 3 SOL-1 trial results for neovascular AMD in 2026?

Ocular Therapeutix will present OTX-TKI Phase 3 SOL-1 efficacy and safety results on July 16, 2026. According to Ocular Therapeutix, this ASRS 44th Annual Meeting session, titled “Beyond Anti-VEGF: Emerging Durable Therapies in Neovascular AMD,” runs from 8:15 to 8:45 AM EDT.

What topics will Ocular Therapeutix cover at the ASRS 44th Annual Meeting in July 2026?

Ocular Therapeutix will cover OTX-TKI SOL-1 Phase 3 results and real-world nAMD anti-VEGF treatment data. According to Ocular Therapeutix, content includes Vestrum database analyses, IRIS Registry treatment patterns, and a satellite symposium on durability and sustained disease control in neovascular AMD.

How can investors watch Ocular Therapeutix at the HC Wainwright Ophthalmology Virtual Conference on July 22, 2026?

Investors can watch a live webcast of Ocular Therapeutix’s fireside chat on July 22, 2026. According to Ocular Therapeutix, the 4:30–5:00 PM EDT session will stream via the Events and Presentations section of its Investor Relations webpage, with a replay archived for at least 30 days.

Who from Ocular Therapeutix will speak at OIS Retina 2026 and ASRS 2026?

Ocular Therapeutix will feature several physician leaders at OIS Retina and ASRS in July 2026. According to Ocular Therapeutix, presenters include Peter K. Kaiser, Dilsher S. Dhoot, Andrew A. Moshfeghi, Priya Vakharia, and symposium faculty including Chief Scientific Officer Jeffrey S. Heier.